NASDAQ:VCEL Vericel (VCEL) Stock Price, News & Analysis $43.75 +0.88 (+2.05%) (As of 10/25/2024 ET) Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends About Vericel Stock (NASDAQ:VCEL) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Vericel alerts:Sign Up Key Stats Today's Range$42.77▼$44.4850-Day Range$40.05▼$53.5652-Week Range$32.28▼$54.10Volume723,693 shsAverage Volume429,385 shsMarket Capitalization$2.13 billionP/E RatioN/ADividend YieldN/APrice Target$57.71Consensus RatingBuy Company OverviewVericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns. The company was formerly known as Aastrom Biosciences, Inc. Vericel Corporation was incorporated in 1989 and is headquartered in Cambridge, Massachusetts.Read More… Tim Sykes’ Urgent Trade Alert: “Make this move now” (Ad)WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT about Trump or Biden dropping out of the race…Click here to see a unique election-year trade Vericel Stock Analysis - MarketRank™See Top Rated MarketRank™ Stocks62nd Percentile Overall ScoreVCEL MarketRank™: Vericel scored higher than 62% of companies evaluated by MarketBeat, and ranked 371st out of 998 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.5 / 5Analyst RatingBuy Consensus RatingVericel has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 7 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageVericel has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Vericel's stock forecast and price target. Earnings and Valuation1.9 / 5Proj. Earnings Growth341.67% Earnings GrowthEarnings for Vericel are expected to grow by 341.67% in the coming year, from $0.12 to $0.53 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Vericel is -4,375,000.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Vericel is -4,375,000.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioVericel has a P/B Ratio of 9.25. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Vericel's valuation and earnings. Short Interest0.0 / 5Short Interest LevelBearish Percentage of Shares Shorted7.92% of the outstanding shares of Vericel have been sold short.Short Interest Ratio / Days to CoverVericel has a short interest ratio ("days to cover") of 11.3, which indicates bearish sentiment.Change versus previous monthShort interest in Vericel has recently increased by 8.45%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldVericel does not currently pay a dividend.Dividend GrowthVericel does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted7.92% of the outstanding shares of Vericel have been sold short.Short Interest Ratio / Days to CoverVericel has a short interest ratio ("days to cover") of 11.3, which indicates bearish sentiment.Change versus previous monthShort interest in Vericel has recently increased by 8.45%, indicating that investor sentiment is decreasing significantly. News and Social Media1.9 / 5News Sentiment0.43 News SentimentVericel has a news sentiment score of 0.43. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.73 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 10 news articles for Vericel this week, compared to 5 articles on an average week. Company Ownership0.8 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Vericel insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,200,764.00 in company stock.Percentage Held by InsidersOnly 5.20% of the stock of Vericel is held by insiders.Read more about Vericel's insider trading history. Receive VCEL Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Vericel and its competitors with MarketBeat's FREE daily newsletter. Email Address VCEL Stock News HeadlinesVericel Co. (NASDAQ:VCEL) Director Steven C. Gilman Sells 5,833 SharesOctober 19, 2024 | insidertrades.comVericel Co. (NASDAQ:VCEL) CEO Dominick Colangelo Sells 17,500 SharesOctober 19, 2024 | insidertrades.comTrump or Kamala? It may come down to this strange twist…Could this be the key to America's second coming? A strange resurrection born in the hollers of Appalachia? To uncover the full story and learn how you can potentially profit from it...October 25, 2024 | Porter & Company (Ad)Vericel Co. (NASDAQ:VCEL) Director Sells $235,361.55 in StockOctober 5, 2024 | insidertrades.comVericel to Report Third-Quarter 2024 Financial Results on November 7, 2024October 24 at 8:30 AM | globenewswire.comVericel Corp. (VCEL) Cooled Down in Q3 After a 20% Rise in the First HalfOctober 22 at 5:20 PM | msn.comVericel Co. (NASDAQ:VCEL) Director Sells $241,252.88 in StockOctober 21, 2024 | americanbankingnews.comDominick Colangelo Sells 17,500 Shares of Vericel Co. (NASDAQ:VCEL) StockOctober 20, 2024 | americanbankingnews.comSee More Headlines VCEL Stock Analysis - Frequently Asked Questions How have VCEL shares performed this year? Vericel's stock was trading at $35.61 at the beginning of the year. Since then, VCEL stock has increased by 22.9% and is now trading at $43.75. View the best growth stocks for 2024 here. How were Vericel's earnings last quarter? Vericel Co. (NASDAQ:VCEL) announced its quarterly earnings results on Thursday, August, 1st. The biotechnology company reported ($0.10) EPS for the quarter, hitting analysts' consensus estimates of ($0.10). Vericel's revenue was up 14.8% compared to the same quarter last year. Who are Vericel's major shareholders? Top institutional shareholders of Vericel include Allspring Global Investments Holdings LLC (0.83%), New York State Teachers Retirement System (0.10%), State of Alaska Department of Revenue (0.06%) and SG Americas Securities LLC (0.05%). Insiders that own company stock include Dominick Colangelo, Robert L Md Zerbe, Joseph Anthony Mara Jr, Steven C Gilman, Jonathan Siegal, Michael Halpin, Sean C Flynn and Jonathan Mark Hopper. View institutional ownership trends. How do I buy shares of Vericel? Shares of VCEL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Vericel own? Based on aggregate information from My MarketBeat watchlists, some other companies that Vericel investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Broadcom (AVGO), Adobe (ADBE), Palo Alto Networks (PANW) and Netflix (NFLX). Company Calendar Last Earnings8/01/2024Today10/25/2024Next Earnings (Confirmed)11/07/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:VCEL CUSIPN/A CIK887359 Webwww.vcel.com Phone(617) 588-5555Fax617-588-5554Employees300Year Founded1989Price Target and Rating Average Stock Price Target$57.71 High Stock Price Target$60.00 Low Stock Price Target$55.00 Potential Upside/Downside+31.9%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage7 Analysts Profitability EPS (Most Recent Fiscal Year)($0.01) Trailing P/E RatioN/A Forward P/E Ratio364.58 P/E GrowthN/ANet Income$-3,180,000.00 Net Margins0.37% Pretax Margin0.75% Return on Equity0.35% Return on Assets0.22% Debt Debt-to-Equity RatioN/A Current Ratio4.50 Quick Ratio4.16 Sales & Book Value Annual Sales$214.52 million Price / Sales9.91 Cash Flow$0.02 per share Price / Cash Flow2,323.80 Book Value$4.73 per share Price / Book9.25Miscellaneous Outstanding Shares48,602,000Free Float46,480,000Market Cap$2.13 billion OptionableOptionable Beta1.67 Social Links Unlock the Potential in Options TradingOptions trading isn’t just for the Wall Street elite; it’s an accessible strategy for anyone armed with the proper knowledge. Think of options as a strategic toolkit, with each tool designed for a specific financial task. Keep reading to learn how options trading can help you use the market’s volatility to your advantage.Get This Free Report This page (NASDAQ:VCEL) was last updated on 10/25/2024 by MarketBeat.com Staff From Our PartnersTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredThe secret supplier behind NVIDIA, Tesla and MicrosoftThe Biggest AI firms in the world...Tesla... Microsoft... NVIDIA... Are all relying on a little-known suppl...Behind the Markets | SponsoredYour financial planner would NEVER tell you thisYour Financial Planner Won't Tell You About This Investment Strategy Silicon Valley insider Jeff Brown has ...Brownstone Research | SponsoredNext opportunity for crypto millions"Uptober" is here, and it's not just a clever name. Historically, October ignites crypto's most explosive g...Crypto 101 Media | SponsoredNvidia is Pivoting to Solve Big Tech’s $1 Trillion ProblemTaiwan Semiconductor, a partner of Nvidia’s for more than two decades, has seen its shares explode as much as ...Weiss Ratings | Sponsored“Hear That Whoosh Sound? It’s the Great Power Suck of 2025”We’re coming to the end of the line for the traditional energy grid. Look what’s happening in California.Traders Agency | SponsoredInvest in the company that won over the DragonsThe pioneer in smart-doorbell technology, RING, pitched their business on the hit show Shark Tank at a valuati...RYSE | SponsoredPutin proposes new currencyRussian leader Vladimir Putin just unveiled the first physical mockup of a proposed new currency. Many spec...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Vericel Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share Vericel With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.